However for a 6 million market cap on a drug company that has around 6 million in cash including R&D rebates, drug that targets the source of brain injury exactly like AGN, GLP results that have so far proven its safety and heading into a fully funded Phase 1 study that proves that the drug is safe and the only drug in the world for both traumatic brain injury and stroke together, compared to AGN only completed phase 1 for stroke, the investment is very compelling with a significant upside coming up.
CEO James is hosting a Webinar next week on non dilutive funding after phase 1 completion hopefully you can attend and stop making lies wasting your time trying to troll on a stock you don’t own
NYR Price at posting:
4.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)